51
Participants
Start Date
September 17, 2019
Primary Completion Date
August 22, 2023
Study Completion Date
August 22, 2023
Treprostinil Inhalation Powder
Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
Penn Medicine University City, Philadelphia
University of Maryland Medical Center Division of Cardiology, Baltimore
Pulmonary Associates of Richmond, Inc., Richmond
Sentara Norfolk General Hospital, Norfolk
Emory University Hospital, Atlanta
Ascension / St. Vincent's Lung Institute, Jacksonville
Mayo Clinic Florida, Jacksonville
Cleveland Clinic Florida, Weston
University of South Florida Center for Advanced Lung Disease, Tampa
University of Alabama at Birmingham, Birmingham
University of Louisville Clinical Trials Unit, Louisville
The University of Kansas Medical Center, Kansas City
Ochsner Medical Center, New Orleans
UT Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles
Lead Sponsor
United Therapeutics
INDUSTRY